M65.2 M65.9 M75.2 M75.4 M75.5 M75.9 M76.6 M76.9 M77.3
Conditions
Interventions
Group 1: Group 1: Radiotherapy only:
Patients in the radiotherapy group receive radiotherapy twice a week (Mon, Fri) using the Orthovolt X-ray 200 machine or a linear accelerator. The target regions c
Sponsors
Universitätsklinik für Strahlentherapie
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - ECOG 0–2, Karnofsky Index >70; - Clinical evidence of a painful inflammatory joint condition (large joints: shoulder, elbow or knee joints; or small joints: ankle joints), inflammatory tendinopathies (NRS = 5) or a heel spur (NRS = 5) with pain lasting more than 3 months and the first onset of pain symptoms occurring less than 2 years ago; - psychological and physical readiness for treatment; - ability to understand and willingness to sign a written informed consent form
Exclusion criteria
Exclusion criteria: - Simultaneous participation in another ongoing study involving medication is prohibited, as this may lead to the results being skewed by synergistic, antagonistic or unpredictable effects on receptors; - Previous radiotherapy in this area; - Other possible causes of pain (e.g. trauma); - Patients at risk of non-compliance; - Lymphoedema; - Pregnant and breastfeeding women; - Illness that may lead to discontinuation of treatment; - Patients unable to give informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| to evaluate the efficacy of water-filtered infrared radiation (wIRA) in the treatment of arthritis, heel spurs and tendinopathies of small and large joints, in comparison with standard procedures (low-dose radiation therapy) and the combination of both methods (wIRA + LDRT), with regard to pain relief. | — |
Secondary
| Measure | Time frame |
|---|---|
| - assessment of treatment tolerability across all groups, patient satisfaction with treatment across all groups, and time to response to therapy across all groups; - analysis of the therapeutic response at the cellular level; - investigation of the correlation between immunological changes and pain reduction; - identification of biomarkers as predictors of treatment success; - Assessment of the correlation between immunological changes and the duration of clinical improvement. | — |
Countries
Germany
Contacts
Public ContactTatiana Lushchaeva
Universitätsklinik für Strahlentherapie
Outcome results
None listed